Bone Biologics (BBLG) 10-Q2023 Q1 Quarterly report

Filed: 15 May 23, 4:18pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: afforded, ago, anti, appeal, ASU, backstopped, beneficial, bid, carrying, charged, compliance, concentration, consecutive, consumed, cure, curve, DBM, deficiency, delisted, delisting, demineralized, difficult, discovery, disruption, dividend, duration, eliminating, establishing, eventually, exact, Extinguishment, extremely, February, framework, freestanding, fully, government, impossible, initial, investment, local, long, matrix, minimum, modified, notice, notify, November, osteopromotive, Panel, permitted, PMA, preliminary, prepaid, progression, put, quotation, receipt, regain, regaining, removing, rendered, retrospective, scope, secure, shareholder, standard, Subtopic, unenforceable, vendor

Removed: absence, accurately, acquired, adjustment, amendment, Antidilutive, beginning, ceased, CFO, consummation, curtailing, Deficit, depended, discontinuance, earliest, employment, existence, Hankey, implement, inability, month, officially, osteostimulative, past, relationship, resuming, revised, scaling, separate, team, Topic

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

BBLG similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification of Principal Executive Officer

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Report of Bone Biologics Corporation (the “Company”) on Form 10-Q for the period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jeffrey Frelick, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	/s/ Jeffrey Frelick
	Jeffrey Frelick
	Principal Executive Officer

	May 15, 2023

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.